Recent Updates — GLUE
On October 1, 2026, Monte Rosa Therapeutics announced positive top-line results from the GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader. The trial enrolled 108 obese subjects with elevated cardiovascular disease risk randomized to 5 mg, 20 mg, or 40 mg doses or placebo for four weeks. MRT-8102 achieved robust target engagement with median NEK7 degradation of 80% to 90% across all dose levels. The treatment substantially reduced local and systemic inflammatory biomarkers, including calprotectin (56%), SAA (51%), hsCRP (85%), and lipoprotein(a) (24%). No serious adverse events were reported, with treatment-emergent adverse event rates similar to placebo (33% vs. 30%). The company plans to initiate Phase 2 studies GFORCE-2 in coronary artery disease (H1 2027), GEMINI-1 in gout (Q4 2026/Q1 2027), and GALAXY-1 in hidradenitis suppurativa (H1 2027). Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines for inflammatory diseases.
On September 8, 2026, Monte Rosa Therapeutics announced that collaborator Novartis initiated a Phase 2 clinical study for MRT-6160 (DDY391) in participants with Sjögren’s disease. This event triggered a $50 million milestone payment from Novartis to Monte Rosa under their global exclusive license agreement. The company remains eligible for up to $2.1 billion in additional development, regulatory, and sales milestones. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines.
Monte Rosa Therapeutics reported second quarter 2026 financial results on August 6, 2026. The company posted a net loss of $43.4 million compared to $12.3 million in the prior year period. Collaboration revenue decreased to $9.0 million from $23.2 million. Research and development expenses rose to $48.0 million due to increased spending on the MRT-8102 program, while general and administrative expenses increased to $10.1 million. The company ended the quarter with a strong balance sheet holding $626.0 million in cash and marketable securities, which is expected to fund operations into 2029. Clinically, Monte Rosa completed enrollment for the GFORCE-1 study of MRT-8102 and activated Phase 2 trials for MRT-2359 in prostate cancer and MRT-6160 in Sjögren’s disease through its Novartis collaboration. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines.